Replies to post #20303 on Mymetics Corp (MYMX)

[Work Harder]

Yep & fwiw the PPD thang was b/c thanks to SP1

Emily Cook
PPD University of Nottingham

https://www.linkedin.com/in/emily-cook-02434a115

liked this today

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158477052

Just another fwiw below

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

Published online 2020 Jun 18

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301105/

13 Matrix M™ Local reaction including pain, tenderness, swelling, and erythema at the injection site. The mild systemic reactions such as headache, myalgia, and fatigue Phase I clinical trial for H5N1 vaccine [141], [142

141. Cox R.J., Pedersen G., Madhun A.S., Svindland S., Sævik M., Breakwell L., Hoschler K., Willemsen M., Campitelli L., Nøstbakken J.K., Weverling G.J. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine. 2011;29(45):8049–8059. [PubMed] [Google Scholar] [Ref list]

142. Pedersen G.K., Sjursen H., Nøstbakken J.K., Jul-Larsen Å., Hoschler K., Cox R.J. Matrix MTM adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man. Human vaccines & immunotherapeutics. 2014;10(8):2408–2416. [PMC free article] [PubMed] [Google Scholar] [Ref list]